Showing results (1171-1180 of 1,190) with videos related to

Sort By:
Pageof 119
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2022
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY ProjectMattia D'Agostino, David A Cairns, Juan José Lahuerta, et al.
The Lancet. Haematology|February 1, 2024
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trialElias K Mai, Hartmut Goldschmid, Kaya Miah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2012
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trialPieter Sonneveld, Ingo G H Schmidt-Wolf, Bronno van der Holt, et al.
The Lancet. Haematology|November 3, 2022
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trialHartmut Goldschmidt, Elias K Mai, Uta Bertsch, et al.
Blood Advances|September 27, 2018
A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosisJulie Støve Bødker, Rasmus Froberg Brøndum, Alexander Schmitz, et al.
Leukemia|August 2, 2017
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trialH Goldschmidt, H M Lokhorst, E K Mai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2024
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 TrialElias K Mai, Uta Bertsch, Ema Pozek, et al.
European Journal of Human Genetics : EJHG|March 20, 2025
Heterozygous CELF4 variants in the N-term region crucial for the RNA-binding activity lead to neurodevelopmental disorder and obesityAnge-Line Bruel, Anneke T Vulto-vanSilfhout, Frédéric Bilan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2026
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 TrialJia Xiang Jin, Varun R Ginde, Stefanie Huhn, et al.
Hemasphere|October 13, 2025
Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN-HARMONY Alliance platformAdrian Mosquera Orgueira, Marta Sonia Gonzalez Perez, Mattia D'Agostino, et al.
Pageof 119